Stage IVB Endometrial Carcinoma: The Role of Cytoreductive Surgery and Determinants of Survival

Bristow, Robert E.; Zerbe, Marc J.; Rosenshein, Neil B.; Grumbine, Francis C.; Montz, F.J.

doi:10.1006/gyno.2000.5843

Cited by 180 publications

(123 citation statements)

References 18 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Only the extent of cytoreduction was a significant predictor of survival on multivariate analysis. Similar findings have been reported by other investigators (Bristow et al 2000;Ayhan et al 2002). Although, data from these small retrospective studies appear encouraging, it is important to note that there has been no randomized trial to date to validate this beneficial effect.…”

Section: Role Of Cytoreductive Surgerysupporting

confidence: 87%

Treatment Strategies and Prognosis of Endometrial Cancer

Garg¹,

Mutch²

2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

Section: Role Of Cytoreductive Surgerysupporting

confidence: 87%

Treatment Strategies and Prognosis of Endometrial Cancer

Garg¹,

Mutch²

2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

“…Over the past few decades, several studies have demonstrated the prognostic importance of different parameters [6][7][8][9][10][11][12]. In this study, 5-years survival of patients was 89%.…”

Section: Discussionmentioning

confidence: 67%

“…Bristow et al [8] and Ferlay et al [19], demonstrated that EC survival decreases in older patients. However, Karateke et al [9], Gottwald et al [12], and Bajracharya and Juan [6], found age at diagnosis was not signifi cant predictor of survival for EC.…”

Section: Discussionmentioning

confidence: 99%

“…The overall 5-year survival for all stages is 86%; patients; when diagnosed at a local or regional stage, the 5-year survival rate is 97% and 67% respectively, while distant stage survival decreases to 16% [7]. In order to improve survival of EC patients, clinic-pathological prognostic factors have been studied previously [5][6][7][8][9][10][11][12]. Unfortunately, the importance of predictive factors for the prognosis of patients with EC has not yet been fully established.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Determinants in Endometrial Cancer Patients: 5-Years Experience

Pınar¹

2017

Arch Nursing Pract Care

View full text Add to dashboard Cite

Aim: The aim of the study was to explore fi ve years survival in women with endometrial cancer. Material and methods:A retrospective review of 146 patients with endometrial cancer treated at Baskent University Hospital Gyne-oncologic Clinic in Ankara, Turkey between 2010 and 2015 was performed. Demographic and clinic-pathological data were compared with survival. Results:The median age of the patients was 61.4 y±5.3 years (36-82). The overall 5-years survival was 89%. Multivariate Cox regression model revealed that the FIGO stage, grade, age, histological type, myometrial invasion, and lymph node involvement were all predictive factors on survival (p<0.05). However, the menopausal status, age at menopause, parity, BMI, comorbidities, ECOG performance score, therapy modality, HR status, and family history were not associated with survival (p>0.05). Conclusion:The results of our study, several clinic-pathological prognostic factors of EC have been identifi ed on survival. These results provided signifi cant evidence that early foresight of EC survival. Further prospective randomized studies are necessary to clarify the role of these factors.

show abstract

“…In all three series, successful cytoreduction was a statistically significant prognostic variable on multivariate analysis. In the work by Bristow et al [18], young age (Ͻ58 years old) and a good performance status was also predictive of survival. Chi and his colleagues saw no difference in survival for those women who presented with optimal stage IV disease (defined as having unresectable carcinomatosis at initial evaluation and not undergoing cytoreduction at all) and those who had a disease burden that was surgically cytoreduced to an optimal extent (defined as a largest residual tumor nodule diameter Յ2 cm), suggesting the importance of aggressive surgery in addition to the role that tumor biology may play in dictating survival [19].…”

Section: Surgery For Stage IV and Recurrent Endometrial Cancermentioning

confidence: 92%

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.2. Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.3. Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTWomen with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previ-

show abstract

Stage IVB Endometrial Carcinoma: The Role of Cytoreductive Surgery and Determinants of Survival

Cited by 180 publications

References 18 publications

Treatment Strategies and Prognosis of Endometrial Cancer

Treatment Strategies and Prognosis of Endometrial Cancer

Survival Determinants in Endometrial Cancer Patients: 5-Years Experience

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Contact Info

Product

Resources

About